Archives
NF-κB p65–Mediated YAP Inactivation Drives Pyroptosis in UC
NF-κB p65–Mediated YAP Inactivation Drives Pyroptosis in Ulcerative Colitis
Study Background and Research Question
Ulcerative colitis (UC) is a chronic, relapsing inflammatory disorder of the colon characterized by mucosal immune dysregulation, epithelial barrier disruption, and cycles of tissue injury and repair. Recent evidence implicates pyroptosis—an inflammatory form of programmed cell death mediated by gasdermin D (GSDMD) and inflammasome activation—as a key driver of epithelial damage and disease progression in UC. While the NF-κB signaling pathway is well-established as a central regulator of inflammatory gene transcription in UC, the precise molecular mechanisms linking NF-κB activity, pyroptotic cell death, and epithelial homeostasis remain incompletely understood.
The study led by Xu et al. (reference article) addresses a critical gap: How does NF-κB p65 influence the Hippo pathway effector Yes-associated protein (YAP) in the context of colonic epithelial pyroptosis, and what are the downstream consequences for UC pathogenesis?
Key Innovation from the Reference Study
This research provides the first direct evidence that NF-κB p65 activation in colonic epithelial cells leads to phosphorylation and cytoplasmic retention of YAP via upregulation of LATS1 kinase. This inactivation of YAP derepresses the inflammasome component NLRP3 at the transcriptional level, thereby facilitating GSDMD-mediated pyroptosis.
A critical innovation is the demonstration that YAP acts as a transcriptional repressor of NLRP3, and that its functional inactivation by the NF-κB pathway removes this regulatory brake, promoting pro-inflammatory cell death. The study integrates molecular, cellular, and animal model evidence to map this axis, moving beyond prior work that considered these pathways in isolation.
Methods and Experimental Design Insights
The investigators employed a multifaceted approach to dissect the NF-κB–YAP–NLRP3 axis in UC:
- In vitro cell model: Pyroptosis was induced in FHC (human colonic epithelial) cells using LPS and ATP. YAP was overexpressed using lentiviral vectors, and genetic manipulations were performed to modulate NF-κB p65 activity.
- Animal model: Acute colitis was induced with dextran sulfate sodium (DSS) in wild-type and GSDMD knockout (GSDMD−/−) mice. YAP was overexpressed via intraperitoneal lentiviral injection.
- Molecular assays: Chromatin immunoprecipitation (ChIP) was used to confirm YAP binding to the NLRP3 promoter. Nucleoplasmic separation and immunoblotting assessed YAP localization and phosphorylation status.
- Inflammatory and pyroptosis markers: Expression of NLRP3, GSDMD, and pro-inflammatory cytokines (IL-1β, IL-6) was quantified in both human UC biopsies and mouse tissues.
This comprehensive design allowed the authors to interrogate causality at multiple levels, from transcriptional regulation to functional phenotypes in disease models.
Core Findings and Why They Matter
The study’s results provide several mechanistic and translational insights:
- NF-κB p65 is upregulated in inflamed colonic epithelium in UC, promoting LATS1-mediated YAP phosphorylation. This prevents YAP nuclear translocation and transcriptional activity.
- Inactivated YAP fails to repress NLRP3 transcription, leading to increased inflammasome assembly and GSDMD-driven pyroptosis.
- YAP overexpression reduces pyroptosis and inflammation in both cell and animal models, but this protective effect is lost in GSDMD-deficient mice, confirming the dependence of disease attenuation on the pyroptotic pathway.
- Human UC tissues and DSS-induced colitis mice show elevated markers of pyroptosis, decreased YAP activity, and increased NLRP3 expression, validating the clinical relevance of the mechanism.
Collectively, these findings suggest that the NF-κB–LATS1–YAP–NLRP3 axis is a central regulatory node controlling epithelial cell fate in UC. Targeting this axis could modulate inflammatory cell death and offer new therapeutic opportunities for intestinal inflammation.
Comparison with Existing Internal Articles
Multiple internal resources, such as "JSH-23: Precise NF-κB Inhibition for Inflammation Research", have outlined the importance of selective NF-κB pathway intervention in dissecting inflammatory mechanisms. These articles highlight JSH-23 as a small molecule NF-κB inhibitor that blocks p65 nuclear translocation, which aligns with the mechanism described by Xu et al. By specifically inhibiting the transcriptional activity of p65, compounds like JSH-23 enable researchers to experimentally isolate the NF-κB-dependent steps in cell fate decisions such as pyroptosis.
Other guides, including scenario-driven workflow recommendations, emphasize the need for robust and reproducible inhibitors to parse NF-κB’s roles in cytokine production, cell viability, and inflammasome regulation. The reference study’s findings provide a mechanistic rationale for deploying such inhibitors in colitis and inflammation research models, especially when investigating cross-talk with the Hippo pathway and cell death programs.
Limitations and Transferability
Despite its strengths, the study is subject to several limitations:
- The cell and animal models may not fully recapitulate the chronic, heterogeneous nature of human UC.
- Genetic manipulation (e.g., YAP overexpression, GSDMD knockout) offers mechanistic clarity but does not directly translate to feasible clinical interventions.
- While the study addresses the link between NF-κB and YAP in pyroptosis, broader impacts on other cell death or repair pathways remain unexplored.
- Transferability to other epithelial tissues or inflammatory diseases requires further investigation.
Nevertheless, the clear demonstration of NF-κB p65’s role in modulating YAP and pyroptosis provides a valuable framework for future inflammation research and preclinical drug testing.
Protocol Parameters
- DSS-induced colitis: Typical induction involves 2–3% DSS in drinking water for 5–7 days to provoke mucosal inflammation and epithelial damage.
- Pyroptosis induction in vitro: Treat FHC cells with 1 μg/mL LPS for 4–6 hours, followed by 5 mM ATP for 30–60 minutes to activate inflammasomes.
- YAP overexpression: Lentiviral constructs administered via intraperitoneal injection in mice (1–2 × 108 PFU/mouse) or transduction in cell culture at MOI 10–20.
- NF-κB pathway modulation: Use of small-molecule inhibitors (e.g., JSH-23) or siRNA for targeted pathway dissection; optimal concentrations and timing should be determined empirically based on model system and readout.
Research Support Resources
For researchers aiming to dissect the NF-κB–YAP–NLRP3 axis or similar inflammatory signaling pathways, validated chemical tools are essential. JSH-23 (SKU B1645) is a structurally characterized NF-κB inhibitor that selectively blocks p65 nuclear translocation and transcriptional activity, enabling precise modulation of downstream inflammatory responses. The product information details its use in both cell-based and animal inflammation models, including established protocols for pro-inflammatory cytokine inhibition and acute injury studies. Researchers can incorporate JSH-23 where targeted NF-κB pathway modulation is required, and APExBIO provides technical resources for optimal reagent handling and experimental design.